Allogene Therapeutics
ALLO
115 hedge funds and large institutions have $1.44B invested in Allogene Therapeutics in 2020 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 41 increasing their positions, 36 reducing their positions, and 16 closing their positions.
14% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 36
0.29% more ownership
Funds ownership: 58.75% → 59.04% (+0.29%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
0% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 16
1% less funds holding
Funds holding: 116 → 115 (-1)
13% less call options, than puts
Call options by funds: $1.69M | Put options by funds: $1.95M
23% less capital invested
Capital invested by funds: $1.86B → $1.44B (-$426M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$57.9M |
| 2 |
Capital International Investors
Los Angeles,
California
|
+$16.5M |
| 3 |
CC
Casdin Capital
New York
|
+$11.9M |
| 4 |
JP Morgan Chase
New York
|
+$7.24M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$5.95M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$30.7M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$15.9M |
| 3 |
VM
VV Manager
Boston,
Massachusetts
|
-$14.3M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$6.34M |
| 5 |
D.E. Shaw & Co
New York
|
-$3.25M |
ALLO Hedge Fund Activity: Q1 2020 in Review
115 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Allogene Therapeutics (ALLO) for Q1 2020, worth a combined $1.44B — down 23% from $1.86B a quarter earlier.
Fund positioning in ALLO was balanced in Q1 2020: 16 funds opened new positions, 16 closed out, 41 added to existing stakes and 36 trimmed.
The largest buyer was Capital Research Global Investors, adding an estimated $57.9M. The largest seller was Fidelity Investments, cutting an estimated $30.7M.
- 115 institutional investors held Allogene Therapeutics (ALLO) as of Q1 2020, down from 116 in Q4 2019.
- Funds reported $1.44B of Allogene Therapeutics stock for Q1 2020, down 23% quarter-over-quarter.
- 16 funds opened new Allogene Therapeutics positions in Q1 2020 and 16 closed out, a net change of 0 holders.
- The largest Allogene Therapeutics buyer in Q1 2020 was Capital Research Global Investors, an estimated $57.9M added.
- The largest Allogene Therapeutics seller in Q1 2020 was Fidelity Investments, an estimated $30.7M sold.
Based on aggregated 13F filings for Q1 2020.